HDAC6-IN-10 is a potent and specific HDAC6 inhibitor, exhibiting an IC50 value of 0.73 nM. It demonstrates remarkable selectivity towards HDAC6, with a selectivity range of 144 to 10,941-fold over other HDAC isoforms. Furthermore, HDAC6-IN-10 exhibits notable anti-proliferative effects on multiple myeloma cells [1].

HDAC5:4370 nM, HDAC11:1800 nM, HDAC9:2560 nM, HDAC7:752 nM, HDAC10:105 nM, HDAC8:513 nM, HDAC6:0.73 nM, HDAC1:8020 nM, HDAC4:5620 nM

HDAC6-IN-10 (Compound 21b) (0.1-10 μM; 24 h) treatment shows highly selective inhibition against HDAC6 [1]. HDAC6-IN-10 (Compound 21b) (0-100 μM; 72 h) treatment shows anti-proliferative activities against two multiple myeloma cells RPMI-8226 and U266 [1]. Western Blot Analysis [1] Cell Line: HCT-116 Concentration: 0.1, 1 and 10 μM Incubation Time: 24 hours Result: Showed a dose-dependent increase in the level of Ac-tubulin. Cell Proliferation Assay [1] Cell Line: RPMI-8226 and U266 cells Concentration: 0-100 μM Incubation Time: 72 hours Result: Showed antiproliferative activities against RPMI-8226 and U266 with the IC 50 s of 33.183 μM and 43.233 μM, respectively.